CA2396810A1 - Sensitive, multiplexed diagnostic assays for protein analysis - Google Patents
Sensitive, multiplexed diagnostic assays for protein analysis Download PDFInfo
- Publication number
- CA2396810A1 CA2396810A1 CA002396810A CA2396810A CA2396810A1 CA 2396810 A1 CA2396810 A1 CA 2396810A1 CA 002396810 A CA002396810 A CA 002396810A CA 2396810 A CA2396810 A CA 2396810A CA 2396810 A1 CA2396810 A1 CA 2396810A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- protein
- kit
- compound
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/6825—Nucleic acid detection involving sensors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1051—Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
Abstract
Disclosed herein are methods for detecting multiple compounds in a sample, involving: (a) contacting the sample with a mixture of binding reagents, the binding reagents being nucleic acid-protein fusions, each having (i) a protein portion which is known to specifically bind to one of the compounds and (ii) a nucleic acid portion which encodes the protein portion and which includes a unique identification tag; (b) allowing the protein portions of the binding reagents and the compounds to form complexes; (c) capturing the binding reagent-compound complexes; (d) amplifying the nucleic acid portions of the complexed binding reagents; and (e) detecting the unique identification tag of each of the amplified nucleic acids, thereby detecting the corresponding compounds in the sample. Also disclosed herein are kits for carrying out such methods.
Description
SENSITIVE, MULTIPLEXED DIAGNOSTIC
ASSAYS FOR PROTEIN ANALYSIS
Background of the Invention In general, the invention relates to diagnostic methods involving multiplex analysis.
A variety of methods exist to detect multiple species in a biological sample. These include ELISA based immunoabsorbent assays, protein biochips, and the like. Each of these methods suffers from limitations in detection sensitivity or selectivity, due, for example, to kinetics of binding or sensitivity of detection reagents. In addition, these techniques are also limited in terms of the number of molecules that can be rapidly detected.
Summary of the Invention The present invention involves a novel multiplex diagnostic approach for the ultra-sensitive detection of molecules in biological samples.
According to this approach, one begins with a set of uniquely defined high affinity binding reagents (typically protein binding reagents).
Each of these reagents binds to a different target in a sample, facilitating the detection of several targets simultaneously. The targets of the binding reagents are frequently proteins, but they may be any moiety capable of specific binding, including, for example, nucleic acids or sugar moieties. Such binding reagents may represent naturally-occurring or partially or completely synthetic amino acid sequences. Examples of naturally-occurring binding reagents include, without limitation, members of the following binding pairs:
antigen/antibody pairs, protein/inhibitor pairs, receptor/ligand pairs (for example cell surface receptor/ligand pairs, such as hormone receptor/peptide hormone pairs), enzyme/substrate pairs (for example, kinase/substrate pairs), lectin/carbohydrate pairs, oligomeric or heterooligomeric protein aggregates, DNA binding protein/DNA binding site pairs, RNA/protein pairs, and nucleic acid duplexes, heteroduplexes, or ligated strands, as well as any molecule which is capable of forming one or more covalent or non-covalent bonds (for example, disulfide bonds) with any portion of a nucleic acid-protein fusion.
In addition to naturally-occurring binding partner members, binding reagents may be derived by any technique, for example, by directed evolution approaches using a desired protein as the binding target.
Whether naturally-occurring or synthetic, when mixtures of binding reagents are utilized in a single diagnostic reaction mixture, they are preferably similar in composition and amino acid length. In a particularly preferred approach, one starts with a common amino acid scaffold or~structural motif that displays the binding domain on one face of the molecule, as is the case for an antibody scaffold that displays CDR regions as a binding region of the molecule. A particularly useful binding scaffold is the 10t'' domain of type III
fibronectin (see, for example, Lipovsek et al., Protein Scaffolds for Antibody Mimics and Other Binding Proteins, U.S.S.N. 09/456,693; U.S.S.N.
09/515,260; U.S.S.N. 09/688,566; WO 00/34784).
The compound to be detected by the present approach may be any substance to which a protein may bind, and is preferably itself a protein.
Such target compounds may be present in any sample, for example, any biological sample. Typical biological samples include, without limitation, any fluid or tissue derived from an organism, for example, a plant or a mammal such as a human.
ASSAYS FOR PROTEIN ANALYSIS
Background of the Invention In general, the invention relates to diagnostic methods involving multiplex analysis.
A variety of methods exist to detect multiple species in a biological sample. These include ELISA based immunoabsorbent assays, protein biochips, and the like. Each of these methods suffers from limitations in detection sensitivity or selectivity, due, for example, to kinetics of binding or sensitivity of detection reagents. In addition, these techniques are also limited in terms of the number of molecules that can be rapidly detected.
Summary of the Invention The present invention involves a novel multiplex diagnostic approach for the ultra-sensitive detection of molecules in biological samples.
According to this approach, one begins with a set of uniquely defined high affinity binding reagents (typically protein binding reagents).
Each of these reagents binds to a different target in a sample, facilitating the detection of several targets simultaneously. The targets of the binding reagents are frequently proteins, but they may be any moiety capable of specific binding, including, for example, nucleic acids or sugar moieties. Such binding reagents may represent naturally-occurring or partially or completely synthetic amino acid sequences. Examples of naturally-occurring binding reagents include, without limitation, members of the following binding pairs:
antigen/antibody pairs, protein/inhibitor pairs, receptor/ligand pairs (for example cell surface receptor/ligand pairs, such as hormone receptor/peptide hormone pairs), enzyme/substrate pairs (for example, kinase/substrate pairs), lectin/carbohydrate pairs, oligomeric or heterooligomeric protein aggregates, DNA binding protein/DNA binding site pairs, RNA/protein pairs, and nucleic acid duplexes, heteroduplexes, or ligated strands, as well as any molecule which is capable of forming one or more covalent or non-covalent bonds (for example, disulfide bonds) with any portion of a nucleic acid-protein fusion.
In addition to naturally-occurring binding partner members, binding reagents may be derived by any technique, for example, by directed evolution approaches using a desired protein as the binding target.
Whether naturally-occurring or synthetic, when mixtures of binding reagents are utilized in a single diagnostic reaction mixture, they are preferably similar in composition and amino acid length. In a particularly preferred approach, one starts with a common amino acid scaffold or~structural motif that displays the binding domain on one face of the molecule, as is the case for an antibody scaffold that displays CDR regions as a binding region of the molecule. A particularly useful binding scaffold is the 10t'' domain of type III
fibronectin (see, for example, Lipovsek et al., Protein Scaffolds for Antibody Mimics and Other Binding Proteins, U.S.S.N. 09/456,693; U.S.S.N.
09/515,260; U.S.S.N. 09/688,566; WO 00/34784).
The compound to be detected by the present approach may be any substance to which a protein may bind, and is preferably itself a protein.
Such target compounds may be present in any sample, for example, any biological sample. Typical biological samples include, without limitation, any fluid or tissue derived from an organism, for example, a plant or a mammal such as a human.
As a central feature of the invention, each of the binding domains is covalently attached to a nucleic acid that encodes the binding domain. Such nucleic acid-protein fusion molecules can be produced by any method, for example, by the method of Roberts and Szostak (Szostak et al., U.S.S.N.
09/007,005 and U.S.S.N. 09/247,190; Szostak et al., VVO 98/31700; Roberts &
Szostak, Proc. Natl. Acad. Sci. USA (1997) vol. 94, p. 12297-12302) using a peptide acceptor, such as puromycin, as a covalent linking agent. As used herein, by a "peptide acceptor" is meant any molecule capable of being added to the C-terminus of a growing protein chain by the catalytic activity of the ribosomal peptidyl transferase function. Typically, such molecules contain (i) a nucleotide or nucleotide-like moiety (for example, adenosine or an adenosine analog (di-methylation at the N-6 amino position is acceptable)), (ii) an amino acid or amino acid-like moiety (for example, any of the 20 D- or L-amino acids or any amino acid analog thereof (for example, O-methyl tyrosine or any of the analogs described by Ellman et al., Meth. Enzymol. 202:301, 1991), and (iii) a linkage between the two (for example, an ester, amide, or ketone linkage at the 3' position or, less preferably, the 2' position); preferably, this linkage does not significantly perturb the pucker of the ring from the natural ribonucleotide conformation. Peptide acceptors may also possess a nucleophile, which may be, without limitation, an amino group, a hydroxyl group, or a sulfhydryl group. In addition, peptide acceptors may be composed of nucleotide mimetics, amino acid mimetics, or mimetics of the combined nucleotide-amino acid structure. As noted above, puromycin represents a preferred peptide acceptor for use in the present method.
In addition to covalently bonded RNA-protein fusions, any other unique, PCR-amplifiable nucleic acid (for example, RNA, DNA, PNA, or any other nucleic acid which includes two or more covalently bonded, naturally-occurring or modified ribonucleotides or deoxyribonucleotides) can be coupled covalently or non-covalently to each individual binding domain. The protein portions of the fusions are typically, composed of naturally-occurring amino acid residues, but may also include amino acid analogs or derivatives, joined by peptide or peptoid bond(s).
Of particular importance is that each binding domain is associated with (and can therefore be identified by) a unique, amplifiable nucleic acid tag, and that each tag in a multiplex reaction is of identical (or essentially identical) length to avoid amplification (for example, PCR) biases. Such unique identification tags are nucleic acid sequences that differ sufficiently in sequence from other tags in a given population or reaction mixture that significant cross-hybridization does not occur under the conditions employed.
These unique identification tags may be present in the protein encoding portion of the fusion (for example, the tag can be a randomized portion of the protein scaffold, such as a randomized loop of the 10'h domain of fibronectin type III).
Alternatively, the unique identification tag can be added to the nucleic acid portion of the fusion molecule and be positioned outside of the nucleic acid sequence which encodes the compound binding domain or, if present, its associated scaffold region. In the latter case, unique identification tags may be chosen which most effectively, most selectively, or most conveniently identify the fusion molecule. For example, if binding reagents are deconvoluted on a DNA chip, tags) may be chosen which best hybridize to immobilized chip nucleic acids) or which are compatible with commercially available chip arrays. Although DNA chips represent a preferred solid support according to the invention, deconvolution may also be carried out on other solid substrates including, without limitation, any other type of chip (for example, silica-based, glass, or gold chip), glass slide, membrane, bead, solid particle (for example, agarose, sepharose, or magnetic bead), column (or column material), membrane (for example, the membrane of a liposome or vesicle), test tube, or microtiter dish.
Using the affinity binding reagents described above, the present method may be carried out, in one preferred embodiment, as follows. The high affinity binding reagents, each containing a unique affinity binding domain and being present in a mixture of anywhere from 1 to 500,000 (each with equilibrium constants of less than 500 nM), are combined with a sample (for example, a biological sample), under conditions which allow each affinity binding domain to reproducibly recognize a binding partner(s). Following complex formation, the complex is captured. This can be accomplished through any standard procedure, for example, by biotinylation of the biological sample, followed by capture of biotinylated complexes using immobilized streptavidin (for example, streptavidin immobilized on magnetic beads or a column). Alternatively, the initial protein sample may be preabsorbed onto a membrane and the binding domains mixed with the membrane. Complexes remain bound, while unbound binding reagents are washed away.
Following capture of bound complexes, binding domains that have bound their targets) in the biological sample are detected simply by performing a PCR reaction using primers which hybridize to the nucleic acid portion of the fusion molecule. Preferably, the PCR reaction is carried out using standard quantitative methods (for example, using Taq Man by Perkin-Elmer).
If multiple complexes are isolated, the isolated pool is then deconvoluted and individual members identified. The identification step may be accomplished through direct sequencing. Alternatively, in a preferred feature of the invention, the isolated pool is deconvoluted and bound analytes identified using DNA chip array detection. In one preferred method, the PCR
reaction is stopped following predefined cycles, and aliquots extracted. In this way, DNA array detection is performed on each aliquot, allowing for quantitative analysis of amounts of each species present in the pool. Again, a critical feature of the PCR step is that the unique identifiable tag is amplified, and that each amplified segment is the result of using identical primers that generate a DNA product of identical (or essentially identical) size.
In addition, the present invention includes kits for carrying out any of the methods described herein. Typically, these kits include at least three important components: (a) a nucleic acid-protein fusion having a protein portion that specifically binds to a desired compound and a nucleic acid portion that both encodes the protein portion and includes a unique identification tag; (b) a PCR primer pair, in which the first primer is designed to hybridize to the nucleic acid portion of the fusion 5' to the unique identification tag and the second primer is designed to hybridize to the nucleic acid portion of the fusion 3' to the unique identification tag and in which hybridization of the primers to the fusion permits amplification of the unique identification tag; and (c) a solid support that includes a nucleic acid that can hybridize to the unique identification tag In preferred embodiments, the kits of the invention may include any of the preferred components discussed above with respect to the preferred methods of the invention.
Use The reagents of the present invention have a multitude of uses in the diagnostic industry and may be substituted for monoclonal antibodies in any use or method for which such antibodies are employed. In addition, the molecules described herein may be used for deconvoluting species in complex biological samples. In addition, the present approach offers a fast, simple way for detecting species using PCR, a detection technique that is virtually unparalleled in its sensitivity. Coupled with the unique advances for PCR in quantitation of individual species and in DNA array platforms for deconvoluting and detecting low levels of species, the present invention represents the state of the art in the diagnostic area.
Other Embodiments Other embodiments are within the claims.
All publications mentioned in this specification are hereby incorporated by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.
What is claimed is:
09/007,005 and U.S.S.N. 09/247,190; Szostak et al., VVO 98/31700; Roberts &
Szostak, Proc. Natl. Acad. Sci. USA (1997) vol. 94, p. 12297-12302) using a peptide acceptor, such as puromycin, as a covalent linking agent. As used herein, by a "peptide acceptor" is meant any molecule capable of being added to the C-terminus of a growing protein chain by the catalytic activity of the ribosomal peptidyl transferase function. Typically, such molecules contain (i) a nucleotide or nucleotide-like moiety (for example, adenosine or an adenosine analog (di-methylation at the N-6 amino position is acceptable)), (ii) an amino acid or amino acid-like moiety (for example, any of the 20 D- or L-amino acids or any amino acid analog thereof (for example, O-methyl tyrosine or any of the analogs described by Ellman et al., Meth. Enzymol. 202:301, 1991), and (iii) a linkage between the two (for example, an ester, amide, or ketone linkage at the 3' position or, less preferably, the 2' position); preferably, this linkage does not significantly perturb the pucker of the ring from the natural ribonucleotide conformation. Peptide acceptors may also possess a nucleophile, which may be, without limitation, an amino group, a hydroxyl group, or a sulfhydryl group. In addition, peptide acceptors may be composed of nucleotide mimetics, amino acid mimetics, or mimetics of the combined nucleotide-amino acid structure. As noted above, puromycin represents a preferred peptide acceptor for use in the present method.
In addition to covalently bonded RNA-protein fusions, any other unique, PCR-amplifiable nucleic acid (for example, RNA, DNA, PNA, or any other nucleic acid which includes two or more covalently bonded, naturally-occurring or modified ribonucleotides or deoxyribonucleotides) can be coupled covalently or non-covalently to each individual binding domain. The protein portions of the fusions are typically, composed of naturally-occurring amino acid residues, but may also include amino acid analogs or derivatives, joined by peptide or peptoid bond(s).
Of particular importance is that each binding domain is associated with (and can therefore be identified by) a unique, amplifiable nucleic acid tag, and that each tag in a multiplex reaction is of identical (or essentially identical) length to avoid amplification (for example, PCR) biases. Such unique identification tags are nucleic acid sequences that differ sufficiently in sequence from other tags in a given population or reaction mixture that significant cross-hybridization does not occur under the conditions employed.
These unique identification tags may be present in the protein encoding portion of the fusion (for example, the tag can be a randomized portion of the protein scaffold, such as a randomized loop of the 10'h domain of fibronectin type III).
Alternatively, the unique identification tag can be added to the nucleic acid portion of the fusion molecule and be positioned outside of the nucleic acid sequence which encodes the compound binding domain or, if present, its associated scaffold region. In the latter case, unique identification tags may be chosen which most effectively, most selectively, or most conveniently identify the fusion molecule. For example, if binding reagents are deconvoluted on a DNA chip, tags) may be chosen which best hybridize to immobilized chip nucleic acids) or which are compatible with commercially available chip arrays. Although DNA chips represent a preferred solid support according to the invention, deconvolution may also be carried out on other solid substrates including, without limitation, any other type of chip (for example, silica-based, glass, or gold chip), glass slide, membrane, bead, solid particle (for example, agarose, sepharose, or magnetic bead), column (or column material), membrane (for example, the membrane of a liposome or vesicle), test tube, or microtiter dish.
Using the affinity binding reagents described above, the present method may be carried out, in one preferred embodiment, as follows. The high affinity binding reagents, each containing a unique affinity binding domain and being present in a mixture of anywhere from 1 to 500,000 (each with equilibrium constants of less than 500 nM), are combined with a sample (for example, a biological sample), under conditions which allow each affinity binding domain to reproducibly recognize a binding partner(s). Following complex formation, the complex is captured. This can be accomplished through any standard procedure, for example, by biotinylation of the biological sample, followed by capture of biotinylated complexes using immobilized streptavidin (for example, streptavidin immobilized on magnetic beads or a column). Alternatively, the initial protein sample may be preabsorbed onto a membrane and the binding domains mixed with the membrane. Complexes remain bound, while unbound binding reagents are washed away.
Following capture of bound complexes, binding domains that have bound their targets) in the biological sample are detected simply by performing a PCR reaction using primers which hybridize to the nucleic acid portion of the fusion molecule. Preferably, the PCR reaction is carried out using standard quantitative methods (for example, using Taq Man by Perkin-Elmer).
If multiple complexes are isolated, the isolated pool is then deconvoluted and individual members identified. The identification step may be accomplished through direct sequencing. Alternatively, in a preferred feature of the invention, the isolated pool is deconvoluted and bound analytes identified using DNA chip array detection. In one preferred method, the PCR
reaction is stopped following predefined cycles, and aliquots extracted. In this way, DNA array detection is performed on each aliquot, allowing for quantitative analysis of amounts of each species present in the pool. Again, a critical feature of the PCR step is that the unique identifiable tag is amplified, and that each amplified segment is the result of using identical primers that generate a DNA product of identical (or essentially identical) size.
In addition, the present invention includes kits for carrying out any of the methods described herein. Typically, these kits include at least three important components: (a) a nucleic acid-protein fusion having a protein portion that specifically binds to a desired compound and a nucleic acid portion that both encodes the protein portion and includes a unique identification tag; (b) a PCR primer pair, in which the first primer is designed to hybridize to the nucleic acid portion of the fusion 5' to the unique identification tag and the second primer is designed to hybridize to the nucleic acid portion of the fusion 3' to the unique identification tag and in which hybridization of the primers to the fusion permits amplification of the unique identification tag; and (c) a solid support that includes a nucleic acid that can hybridize to the unique identification tag In preferred embodiments, the kits of the invention may include any of the preferred components discussed above with respect to the preferred methods of the invention.
Use The reagents of the present invention have a multitude of uses in the diagnostic industry and may be substituted for monoclonal antibodies in any use or method for which such antibodies are employed. In addition, the molecules described herein may be used for deconvoluting species in complex biological samples. In addition, the present approach offers a fast, simple way for detecting species using PCR, a detection technique that is virtually unparalleled in its sensitivity. Coupled with the unique advances for PCR in quantitation of individual species and in DNA array platforms for deconvoluting and detecting low levels of species, the present invention represents the state of the art in the diagnostic area.
Other Embodiments Other embodiments are within the claims.
All publications mentioned in this specification are hereby incorporated by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.
What is claimed is:
Claims (39)
1. A method for detecting multiple compounds in a sample, said method comprising:
(a) contacting said sample with a mixture of binding reagents, said binding reagents being nucleic acid-protein fusions, each having (i) a protein portion which is known to specifically bind to one of said compounds and (ii) a nucleic acid portion which encodes said protein portion and which includes a unique identification tag;
(b) allowing said protein portions of said binding reagents and said compounds to form complexes;
(c) capturing said binding reagent-compound complexes;
(d) amplifying said nucleic acid portions of said complexed binding reagents; and (e) detecting said unique identification tag of each of said amplified nucleic acids, thereby detecting the corresponding compounds in said sample.
(a) contacting said sample with a mixture of binding reagents, said binding reagents being nucleic acid-protein fusions, each having (i) a protein portion which is known to specifically bind to one of said compounds and (ii) a nucleic acid portion which encodes said protein portion and which includes a unique identification tag;
(b) allowing said protein portions of said binding reagents and said compounds to form complexes;
(c) capturing said binding reagent-compound complexes;
(d) amplifying said nucleic acid portions of said complexed binding reagents; and (e) detecting said unique identification tag of each of said amplified nucleic acids, thereby detecting the corresponding compounds in said sample.
2. The method of claim 1, wherein said sample is a biological sample.
3. The method of claim 1, wherein said nucleic acid-protein fusion is an RNA-protein fusion.
4. The method of claim 1, wherein said nucleic acid-protein fusion is covalently bound.
5. The method of claim 4, wherein said nucleic acid-protein fusion is covalently bound through a peptide acceptor.
6. The method of claim 5, wherein said peptide acceptor is puromycin.
7. The method of claim 1, wherein said binding reagents do not bind said compounds through compound-specific antibody domains.
8. The method of claim 1, wherein each of said binding reagents comprises a scaffold domain.
9. The method of claim 8, wherein each of said binding reagents comprises a fibronectin scaffold domain.
10. The method of claim 9, wherein said fibronectin scaffold domain is the 10 th domain of fibronectin type III.
11. The method of claim 8, wherein each of said binding reagents comprises an antibody scaffold domain.
12. The method of claim 1, wherein said binding reagents bind said compounds with equilibrium constants of less than about 500 nM.
13. The method of claim 1, wherein said unique identification tags are detected using a solid support to which are immobilized nucleic acids specific for said unique identification tags and said detection is accomplished by hybridization of said unique identification tags to said immobilized nucleic acids.
14. The method of claim 1, wherein said amplifying step (d) is carried out using quantitative PCR.
15. The method of claim 1, wherein said compounds are proteins.
16. The method of claim 1, wherein said mixture of binding reagents comprises at least 5 different nucleic acid-protein fusions, each specifically binding to a different compound.
17. The method of claim 16, wherein said mixture of binding reagents comprises at least 100 different nucleic acid-protein fusions, each specifically binding to a different compound.
18. The method of claim 17, wherein said mixture of binding reagents comprises at least 40,000 different nucleic acid-protein fusions, each specifically binding to a different compound.
19. The method of claim 18, wherein said mixture of binding reagents comprises at least 500,000 different nucleic acid-protein fusions, each specifically binding to a different compound.
20. A method for detecting a compound in a sample, said method comprising:
(a) contacting said sample with a binding reagent, said binding reagent being a nucleic acid-protein fusion having (i) a protein portion which is known to specifically bind to said compound and (ii) a nucleic acid portion which encodes said protein portion and which includes a unique identification tag;
(b) allowing said protein portion of said binding reagent and said compound to form a complex;
(c) capturing said binding reagent-compound complex;
(d) amplifying said nucleic acid portion of said complexed binding reagent; and (e) detecting said unique identification tag of said amplified nucleic acid, thereby detecting the corresponding compound in said sample.
(a) contacting said sample with a binding reagent, said binding reagent being a nucleic acid-protein fusion having (i) a protein portion which is known to specifically bind to said compound and (ii) a nucleic acid portion which encodes said protein portion and which includes a unique identification tag;
(b) allowing said protein portion of said binding reagent and said compound to form a complex;
(c) capturing said binding reagent-compound complex;
(d) amplifying said nucleic acid portion of said complexed binding reagent; and (e) detecting said unique identification tag of said amplified nucleic acid, thereby detecting the corresponding compound in said sample.
21. A kit for carrying out compound detection, said kit comprising:
(a) a nucleic acid-protein fusion, wherein said protein portion of said fusion specifically binds said compound and said nucleic acid portion of said fusion encodes said protein portion and includes a unique identification tag;
(b) a PCR primer pair, wherein the first of said primers hybridizes to said nucleic acid portion of said fusion 5' to said unique identification tag and the second of said primers hybridizes to said nucleic acid portion of said fusion 3' to said unique identification tag and hybridization of said primers to said nucleic acid fusion permits amplification of said unique identification tag;
and (c) a solid support comprising a nucleic acid which can hybridize to said unique identification tag.
(a) a nucleic acid-protein fusion, wherein said protein portion of said fusion specifically binds said compound and said nucleic acid portion of said fusion encodes said protein portion and includes a unique identification tag;
(b) a PCR primer pair, wherein the first of said primers hybridizes to said nucleic acid portion of said fusion 5' to said unique identification tag and the second of said primers hybridizes to said nucleic acid portion of said fusion 3' to said unique identification tag and hybridization of said primers to said nucleic acid fusion permits amplification of said unique identification tag;
and (c) a solid support comprising a nucleic acid which can hybridize to said unique identification tag.
22. The kit of claim 21, wherein said kit further comprises Taq polymerase.
23. The kit of claim 21, wherein said nucleic acid-protein fusion is an RNA-protein fusion.
24. The kit of claim 21, wherein said nucleic acid-protein fusion is covalently bound.
25. The kit of claim 24, wherein said nucleic acid-protein fusion is covalently bound through a peptide acceptor.
26. The kit of claim 25, wherein said peptide acceptor is puromycin.
27. The kit of claim 21, wherein said nucleic acid-protein fusion does not bind said compound through a compound-specific antibody domain.
28. The kit of claim 21, wherein said nucleic acid-protein fusion comprises a scaffold domain.
29. The kit of claim 28, wherein nucleic acid-protein fusion comprises a fibronectin scaffold domain.
30. The kit of claim 29, wherein said fibronectin scaffold domain is the 10 th domain of fibronectin type III.
31. The kit of claim 28, wherein said nucleic acid-protein fusion comprises an antibody scaffold domain.
32. The kit of claim 21, wherein said nucleic acid-protein fusion binds said compound with an equilibrium constant of less than about 500 nM.
33. The kit of claim 21, wherein said solid support is a chip.
34. The kit of claim 21, wherein said solid support comprises an ordered array of single-stranded nucleic acids on its surface, each of said single-stranded nucleic acids being capable of hybridizing to a different said unique identification tag.
35. The kit of claim 21, wherein said compound is a protein.
36. The kit of claim 21, wherein said kit comprises at least 5 different nucleic acid-protein fusions, each specifically binding to a different compound.
37. The kit of claim 36, wherein said kit comprises at least 100 different nucleic acid-protein fusions, each specifically binding to a different compound.
38. The kit of claim 37, wherein said kit comprises at least 40,000 different nucleic acid-protein fusions, each specifically binding to a different compound.
39. The kit of claim 38, wherein said kit comprises at least 500,000 different nucleic acid-protein fusions, each specifically binding to a different compound.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17787300P | 2000-01-24 | 2000-01-24 | |
| US60/177,873 | 2000-01-24 | ||
| PCT/US2001/000291 WO2001053539A1 (en) | 2000-01-24 | 2001-01-04 | Sensitive, multiplexed diagnostic assays for protein analysis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2396810A1 true CA2396810A1 (en) | 2001-07-26 |
Family
ID=22650272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002396810A Abandoned CA2396810A1 (en) | 2000-01-24 | 2001-01-04 | Sensitive, multiplexed diagnostic assays for protein analysis |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6489116B2 (en) |
| EP (1) | EP1250463B1 (en) |
| JP (1) | JP2003520050A (en) |
| AT (1) | ATE322558T1 (en) |
| AU (1) | AU783689B2 (en) |
| CA (1) | CA2396810A1 (en) |
| DE (1) | DE60118527D1 (en) |
| WO (1) | WO2001053539A1 (en) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004532981A (en) * | 2001-04-10 | 2004-10-28 | チルドレンズ メディカル センター コーポレーション | Methods for analyzing and labeling protein-protein interactions |
| WO2002102820A1 (en) | 2001-06-20 | 2002-12-27 | Nuevolution A/S | Nucleoside derivatives for library preparation |
| EP1419274A4 (en) * | 2001-07-31 | 2006-02-08 | Phylos Inc | Modular assembly of nucleic acid-protein fusion multimers |
| DE10145226A1 (en) * | 2001-09-13 | 2003-04-10 | Lifebits Ag | Manufacture of carrier-bound molecules |
| US7045311B2 (en) * | 2001-10-25 | 2006-05-16 | Monogram Biosciences, Inc. | Whole cell assay systems for cell surface proteases |
| AU2002365404A1 (en) * | 2001-11-27 | 2003-06-10 | Compound Therapeutics, Inc. | Solid-phase immobilization of proteins and peptides |
| WO2003061570A2 (en) * | 2002-01-16 | 2003-07-31 | Zyomyx, Inc. | Engineered binding proteins |
| US20030166010A1 (en) * | 2002-02-25 | 2003-09-04 | Affholter Joseph A. | Custom ligand design for biomolecular filtration and purification for bioseperation |
| DE60324778D1 (en) | 2002-03-15 | 2009-01-02 | Nuevolution As | AN IMPROVED METHOD FOR SYNTHESIS OF MATTRESS-RELATED MOLECULES |
| US20030198973A1 (en) * | 2002-04-23 | 2003-10-23 | The Molecular Sciences Institute, Inc. | Chimeric fusion molecule for analyte detection and quantitation |
| US20040229294A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
| US7402397B2 (en) | 2002-05-21 | 2008-07-22 | Monogram Biosciences, Inc. | Detecting and profiling molecular complexes |
| US10730906B2 (en) | 2002-08-01 | 2020-08-04 | Nuevolutions A/S | Multi-step synthesis of templated molecules |
| ATE513055T1 (en) | 2002-10-30 | 2011-07-15 | Nuevolution As | ENZYMATIC CODING |
| US9121110B2 (en) | 2002-12-19 | 2015-09-01 | Nuevolution A/S | Quasirandom structure and function guided synthesis methods |
| EP1597395A2 (en) | 2003-02-21 | 2005-11-23 | Nuevolution A/S | Method for producing second-generation library |
| JP5117719B2 (en) * | 2003-04-18 | 2013-01-16 | ベクトン・ディキンソン・アンド・カンパニー | Immune amplification |
| EP1625232B1 (en) * | 2003-05-16 | 2013-09-04 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Internal control nucleic acid molecule for nucleic acid amplification systems |
| EP2711025A3 (en) * | 2003-06-25 | 2014-09-10 | Massachusetts Institute of Technology | Self-assembling peptides incorporating modifications and methods of use thereof |
| US7713923B2 (en) | 2003-06-25 | 2010-05-11 | Massachusetts Institute Of Technology | Self-assembling peptides incorporating modifications and methods of use thereof |
| EP1670939B1 (en) * | 2003-09-18 | 2009-11-04 | Nuevolution A/S | A method for obtaining structural information concerning an encoded molecule and method for selecting compounds |
| EP1681983A4 (en) * | 2003-10-14 | 2008-12-10 | Monogram Biosciences Inc | Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy |
| US7785843B2 (en) * | 2004-06-23 | 2010-08-31 | Sequenom, Inc. | Target-specific compomers and methods of use |
| US20060110724A1 (en) | 2004-11-19 | 2006-05-25 | Burkhardt William Iii | Quantitative real-time assay for noroviruses and enteroviruses with built in quality control standard |
| US20060204999A1 (en) * | 2005-03-14 | 2006-09-14 | Stephen Macevicz | Detecting molecular complexes |
| ES2427565T3 (en) * | 2005-04-25 | 2013-10-31 | Massachusetts Institute Of Technology | Self-assembling peptides to promote hemostasis |
| US20090018029A1 (en) | 2005-11-16 | 2009-01-15 | Ambrx, Inc. | Methods and Compositions Comprising Non-Natural Amino Acids |
| ES2901551T3 (en) | 2005-12-01 | 2022-03-22 | Nuevolution As | Enzymatic Encoding Methods for Efficient Synthesis of Large Libraries |
| EP2012842B1 (en) | 2006-04-25 | 2018-04-04 | Massachusetts Institute of Technology | Compositions and methods for affecting movement of contaminants, bodily fluids or other entities and/or affecting other physiological conditions |
| WO2008039483A2 (en) * | 2006-09-26 | 2008-04-03 | Massachusetts Institute Of Technology | Modified self-assembling peptides |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| WO2009073569A2 (en) | 2007-11-30 | 2009-06-11 | Abbott Laboratories | Protein formulations and methods of making same |
| EP3629022A1 (en) | 2008-07-25 | 2020-04-01 | Richard W. Wagner | Protein screening methods |
| WO2011072482A1 (en) | 2009-12-14 | 2011-06-23 | The University Of Hong Kong | Nano cancer barrier device(ncbd) to immobilize and inhibit the division of metastic cancer stem cells |
| WO2011127933A1 (en) | 2010-04-16 | 2011-10-20 | Nuevolution A/S | Bi-functional complexes and methods for making and using such complexes |
| ES2926988T3 (en) | 2011-03-15 | 2022-10-31 | X Body Inc | Antibody screening methods |
| CA3078215A1 (en) | 2011-04-28 | 2012-11-01 | Department Of Veterans Affairs | Identification of polynucleotides associated with a sample |
| JP6483442B2 (en) | 2011-12-05 | 2019-03-13 | エックス−ボディ インコーポレイテッド | PDGF receptor beta-binding polypeptide |
| GB2504240B (en) | 2012-02-27 | 2015-05-27 | Cellular Res Inc | Compositions and kits for molecular counting of nucleic acids |
| ES2920601T3 (en) | 2013-06-28 | 2022-08-05 | X Body Inc | Discovery of target antigens, phenotypic screens and use thereof for the identification of specific target epitopes of target cells |
| KR102536833B1 (en) | 2013-08-28 | 2023-05-26 | 벡톤 디킨슨 앤드 컴퍼니 | Massively parallel single cell analysis |
| CA2924879C (en) | 2013-09-23 | 2023-01-10 | X-Body, Inc. | Methods and compositions for generation of binding agents against cell surface antigens |
| SG10202005892SA (en) * | 2014-06-06 | 2020-07-29 | Herlev Hospital | Determining antigen recognition through barcoding of mhc multimers |
| WO2015188839A2 (en) | 2014-06-13 | 2015-12-17 | Immudex Aps | General detection and isolation of specific cells by binding of labeled molecules |
| EP3262192B1 (en) | 2015-02-27 | 2020-09-16 | Becton, Dickinson and Company | Spatially addressable molecular barcoding |
| EP4180535A1 (en) | 2015-03-30 | 2023-05-17 | Becton, Dickinson and Company | Methods and compositions for combinatorial barcoding |
| EP3286326A1 (en) | 2015-04-23 | 2018-02-28 | Cellular Research, Inc. | Methods and compositions for whole transcriptome amplification |
| US10619186B2 (en) | 2015-09-11 | 2020-04-14 | Cellular Research, Inc. | Methods and compositions for library normalization |
| US10301677B2 (en) | 2016-05-25 | 2019-05-28 | Cellular Research, Inc. | Normalization of nucleic acid libraries |
| US10202641B2 (en) | 2016-05-31 | 2019-02-12 | Cellular Research, Inc. | Error correction in amplification of samples |
| US10640763B2 (en) | 2016-05-31 | 2020-05-05 | Cellular Research, Inc. | Molecular indexing of internal sequences |
| SG11201901733PA (en) | 2016-09-26 | 2019-04-29 | Cellular Res Inc | Measurement of protein expression using reagents with barcoded oligonucleotide sequences |
| US11319583B2 (en) | 2017-02-01 | 2022-05-03 | Becton, Dickinson And Company | Selective amplification using blocking oligonucleotides |
| AU2018281745B2 (en) | 2017-06-05 | 2022-05-19 | Becton, Dickinson And Company | Sample indexing for single cells |
| WO2019213237A1 (en) | 2018-05-03 | 2019-11-07 | Becton, Dickinson And Company | Molecular barcoding on opposite transcript ends |
| JP7407128B2 (en) | 2018-05-03 | 2023-12-28 | ベクトン・ディキンソン・アンド・カンパニー | High-throughput multi-omics sample analysis |
| CN112805389A (en) | 2018-10-01 | 2021-05-14 | 贝克顿迪金森公司 | Determination of 5' transcript sequences |
| JP2022506546A (en) | 2018-11-08 | 2022-01-17 | ベクトン・ディキンソン・アンド・カンパニー | Single-cell whole transcriptome analysis using random priming |
| EP3894552A1 (en) | 2018-12-13 | 2021-10-20 | Becton, Dickinson and Company | Selective extension in single cell whole transcriptome analysis |
| ES2945227T3 (en) | 2019-01-23 | 2023-06-29 | Becton Dickinson Co | Antibody Associated Oligonucleotides |
| US11939622B2 (en) | 2019-07-22 | 2024-03-26 | Becton, Dickinson And Company | Single cell chromatin immunoprecipitation sequencing assay |
| US11773436B2 (en) | 2019-11-08 | 2023-10-03 | Becton, Dickinson And Company | Using random priming to obtain full-length V(D)J information for immune repertoire sequencing |
| CN115244184A (en) | 2020-01-13 | 2022-10-25 | 贝克顿迪金森公司 | Methods and compositions for quantifying protein and RNA |
| WO2021231779A1 (en) | 2020-05-14 | 2021-11-18 | Becton, Dickinson And Company | Primers for immune repertoire profiling |
| US11932901B2 (en) | 2020-07-13 | 2024-03-19 | Becton, Dickinson And Company | Target enrichment using nucleic acid probes for scRNAseq |
| EP4247967A1 (en) | 2020-11-20 | 2023-09-27 | Becton, Dickinson and Company | Profiling of highly expressed and lowly expressed proteins |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
| DE3546807C2 (en) | 1985-03-30 | 1991-03-28 | Marc Genf/Geneve Ch Ballivet | |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| ATE168416T1 (en) | 1989-10-05 | 1998-08-15 | Optein Inc | CELL-FREE SYNTHESIS AND ISOLATION OF GENES AND POLYPEPTIDES |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| WO1992002536A1 (en) | 1990-08-02 | 1992-02-20 | The Regents Of The University Of Colorado | Systematic polypeptide evolution by reverse translation |
| US5264563A (en) | 1990-08-24 | 1993-11-23 | Ixsys Inc. | Process for synthesizing oligonucleotides with random codons |
| DE4112440C1 (en) | 1991-04-16 | 1992-10-22 | Diagen Institut Fuer Molekularbiologische Diagnostik Gmbh, 4000 Duesseldorf, De | |
| US5795747A (en) | 1991-04-16 | 1998-08-18 | Evotec Biosystems Gmbh | Process for manufacturing new biopolymers |
| AU2313392A (en) | 1991-08-01 | 1993-03-02 | University Research Corporation | Systematic polypeptide evolution by reverse translation |
| US5639603A (en) | 1991-09-18 | 1997-06-17 | Affymax Technologies N.V. | Synthesizing and screening molecular diversity |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
| US5541061A (en) | 1992-04-29 | 1996-07-30 | Affymax Technologies N.V. | Methods for screening factorial chemical libraries |
| US5565324A (en) | 1992-10-01 | 1996-10-15 | The Trustees Of Columbia University In The City Of New York | Complex combinatorial chemical libraries encoded with tags |
| US6087186A (en) | 1993-07-16 | 2000-07-11 | Irori | Methods and apparatus for synthesizing labeled combinatorial chemistry libraries |
| US5635602A (en) | 1993-08-13 | 1997-06-03 | The Regents Of The University Of California | Design and synthesis of bispecific DNA-antibody conjugates |
| WO1995011922A1 (en) | 1993-10-29 | 1995-05-04 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| PT1231268E (en) | 1994-01-31 | 2005-11-30 | Univ Boston | BANKS OF POLYCLONE ANTIBODIES |
| US5561043A (en) | 1994-01-31 | 1996-10-01 | Trustees Of Boston University | Self-assembling multimeric nucleic acid constructs |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| JPH10500951A (en) | 1994-05-23 | 1998-01-27 | スミスクライン・ビーチャム・コーポレイション | Coded combinatorial library |
| US5627024A (en) | 1994-08-05 | 1997-05-06 | The Scripps Research Institute | Lambdoid bacteriophage vectors for expression and display of foreign proteins |
| US5559000A (en) | 1995-01-18 | 1996-09-24 | The Scripps Research Institute | Encoded reaction cassette |
| US5751629A (en) | 1995-04-25 | 1998-05-12 | Irori | Remotely programmable matrices with memories |
| DE19646372C1 (en) | 1995-11-11 | 1997-06-19 | Evotec Biosystems Gmbh | Conjugates of polypeptide and encoding nucleic acid |
| WO1998016636A1 (en) | 1996-10-17 | 1998-04-23 | Mitsubishi Chemical Corporation | Molecule that homologizes genotype and phenotype and utilization thereof |
| AU738328B2 (en) | 1997-01-21 | 2001-09-13 | General Hospital Corporation, The | Selection of proteins using RNA-protein fusions |
| US6261804B1 (en) * | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
| GB9703369D0 (en) * | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| GB9712512D0 (en) | 1997-06-16 | 1997-08-20 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| US6537749B2 (en) * | 1998-04-03 | 2003-03-25 | Phylos, Inc. | Addressable protein arrays |
| US5985575A (en) | 1998-05-20 | 1999-11-16 | Wisconsin Alumni Research Foundation | Tethered function assay for protein function |
| DE69941193D1 (en) | 1998-08-17 | 2009-09-10 | Bristol Myers Squibb Co | IDENTIFICATION OF COMPOUND PROTEIN INTERACTIONS WITH LIBRARIES OF COUPLED PROTEIN NUCLEIC ACID MOLECULES |
| JP4808315B2 (en) * | 1998-12-02 | 2011-11-02 | ブリストル−マイヤーズ スクウィブ カンパニー | DNA / protein fusion and its use |
| DE69941267D1 (en) | 1998-12-10 | 2009-09-24 | Bristol Myers Squibb Co | PROTEIN EQUIPMENT FOR ANTIBODY-NACHHAMMER AND OTHER BINDING PROTEINS |
-
2001
- 2001-01-04 DE DE60118527T patent/DE60118527D1/en not_active Expired - Lifetime
- 2001-01-04 JP JP2001553398A patent/JP2003520050A/en active Pending
- 2001-01-04 CA CA002396810A patent/CA2396810A1/en not_active Abandoned
- 2001-01-04 WO PCT/US2001/000291 patent/WO2001053539A1/en active IP Right Grant
- 2001-01-04 EP EP01942678A patent/EP1250463B1/en not_active Expired - Lifetime
- 2001-01-04 AT AT01942678T patent/ATE322558T1/en not_active IP Right Cessation
- 2001-01-04 US US09/755,663 patent/US6489116B2/en not_active Expired - Lifetime
- 2001-01-04 AU AU29279/01A patent/AU783689B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE60118527D1 (en) | 2006-05-18 |
| WO2001053539A1 (en) | 2001-07-26 |
| EP1250463A1 (en) | 2002-10-23 |
| US20010024784A1 (en) | 2001-09-27 |
| ATE322558T1 (en) | 2006-04-15 |
| JP2003520050A (en) | 2003-07-02 |
| AU783689B2 (en) | 2005-11-24 |
| US6489116B2 (en) | 2002-12-03 |
| AU2927901A (en) | 2001-07-31 |
| EP1250463B1 (en) | 2006-04-05 |
| EP1250463A4 (en) | 2004-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1250463B1 (en) | Sensitive, multiplexed diagnostic assays for protein analysis | |
| US7022479B2 (en) | Sensitive, multiplexed diagnostic assays for protein analysis | |
| EP0779934B1 (en) | Compositions and methods for use in detection of analytes | |
| AU634969B2 (en) | Method and reagents for detecting nucleic acid sequences | |
| EP2044219B1 (en) | Detectable nucleic acid tag | |
| US5702893A (en) | Hydrophobic nucleic acid probe | |
| CA2400384A1 (en) | Methods and kits for proximity probing | |
| JP2001517068A (en) | Nucleic acid capture component | |
| JP3130538B2 (en) | High sensitivity fluorescence assay | |
| EP1041160A1 (en) | Methods for detecting mutation in base sequence | |
| JP4672234B2 (en) | Method and test kit for quantification of variation in polynucleotide content in a cell or tissue sample | |
| Vary | Triple-helical capture assay for quantification of polymerase chain reaction products | |
| US20030082571A1 (en) | Linear nucleic acid and sequence therefor | |
| JP2002017399A (en) | Method of detecting base polymorphism | |
| US20050239078A1 (en) | Sequence tag microarray and method for detection of multiple proteins through DNA methods | |
| WO1989009281A1 (en) | Method for amplifying and detecting nucleic acid in a test liquid | |
| JP2001269197A (en) | Immobilized oligonucleotide probe | |
| JPH02215399A (en) | Detection of nucleic acid | |
| KR20070083924A (en) | Nucleic acid fragments for detecting nucleic acid and method of detecting nucleic acid | |
| JP3103806B1 (en) | Nucleic acid detection method | |
| US20040121331A1 (en) | Methods of amplifying signals in multiplexed protein analysis | |
| WO2024084249A1 (en) | Clonal amplification | |
| JP2002209584A (en) | Method for detecting nucleotide polymorphism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |